Positron emission tomography (PET) is a useful procedure for assessing the density (Phelps, 2000) and pharmacological properties of receptors in vivo (Merlet et al., 1993;Beugel et al., 1999). However, receptor-PET studies favor radioligands that are either stable in the body or that give rise to metabolites that do not interfere with the imaging of specifically bound ligand.The ligand (Holschbach et al., 2002) is used to image the A 1 adenosine receptor (A 1 AR) in human brain (Bauer et al., 2003). Because this ligand does not undergo degradation in the central nervous system, specifically bound ligand accounts for a very large fraction of brain radioactivity. However, such is not the case in peripheral tissues. The metabolism of [18 F]CPFPX in primates (Boy et al., 1998) and humans gives rise to at least three polar metabolites in blood, and studies illustrated the confounding effects of these metabolites. For example, the intravenous administration of [18 F]CPFPX to experimental animals caused intense labeling of the heart that was unaffected by the administration of unlabeled ligand, evidence for high unspecific binding of a metabolite (Holschbach et al., 1998).The physiological importance of the A 1 AR, its wide tissue distribution, and the success of PET-imaging A 1 ARs in the central nervous system urge extension of this technique to other organs. The design of more stable radioligands to achieve that end requires the kind of information about the metabolism of [18 F]CPFPX provided by this study.Measurements of receptor density by PET depend on compartmental analysis by mathematical models that are very sensitive to the concentration of native radioligand in blood perfusing the organ (the "input function"). Such measurements on the plasma of human subjects (Meyer et al., 2004) identified several [18 F]CPFPX metabolites in addition to unchanged ligand. Because the radiotracers for PET studies are prepared under no-carrier-added conditions, the amount of compound administered is in the low to subnanomolar range, making direct spectrometric identification of metabolites impossible. As this report describes, incubating CPFPX with human liver microsomes generated compounds that by HPLC had the same mobilities as the metabolites in plasma, and LC-MS tentatively identified them by measuring m/z of the [M ϩ H] ϩ ions. The literature contains little information about the metabolism of synthetic xanthines. The use of CPFPX in humans for diagnostic and research PET imaging necessitates the knowledge of its metabolism in vivo. To our knowledge, the present study of the biotransformation of CPFPX in humans is the first of its kind.Article, publication date, and citation information can be found at